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Abstract : Objective : The purpose of the present study is to examine clinical factors related to life skills in people 
with schizophrenia. Method : The participants were 51 stabilized outpatients with schizophrenia. Their mean 
age was 38.91 (SD = 10.73) years. Life skills were assessed using the Life skills profile (LSP). Cognitive function 
was evaluated with the Measurement and Treatment Research to Improve Cognition in Schizophrenia Con-
sensus Cognitive Battery (MCCB). Clinical symptoms were assessed using the Positive and Negative Syndrome 
scale (PANSS), the Calgary Depression Scale for Schizophrenia (CDSS) and the Drug-Induced Extrapyramidal 
Symptoms Scale (DIEPSS). Results : Cognitive function was not correlated with the LSP scores at all. Among 
clinical symptoms, scores of the PANSS positive and negative syndrome scales, the CDSS, and the DIEPSS had 
negative correlations with the LSP total score and the subscales. Stepwise regression analyses showed that the 
CDSS and PANSS negative syndrome scale scores were independent predictors of the LSP total score and two 
of the subscales. Conclusions : These results indicate that cognitive function is not associated with life skills but 
clinical symptoms such as depressive and negative symptoms have considerable impacts on life skills in people 
with schizophrenia. J. Med. Invest. 67 : 75-82, February, 2020
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INTRODUCTION
 
Functional outcome is defined as wide-ranging real-world 
functions including independent living, financial management, 
employment and leisure/social activities (1,2), and it is known 
that poor functional outcome is common in patients with schizo-
phrenia (3-7). Therefore, finding contributors to functional out-
come is an important issue in schizophrenia research. Previous 
studies have shown that several clinical factors such as positive, 
negative, depressive and extrapyramidal symptoms are associat-
ed with functional impairments (8-21).
Recently, much more attention has been paid to cognitive 
impairment of schizophrenia patients because it is considered to 
be a core feature of schizophrenia (22,23). Previous researchers 
have found that cognitive impairment persists throughout the 
illness and exists even in premorbid period (24,25). According 
to the previous reports, patients with schizophrenia have about 
1-1.5 standard deviations deficits compared to healthy controls 
in several cognitive domains, particularly memory, attention, 
executive function and speed of processing (26-28). Previous 
studies also have indicated that neurocognition such as verbal 
memory, working memory, executive function and vigilance 
are related to functional outcome in people with schizophrenia 
(29-31), and that neurocognition may be a stronger predictor of 
functional outcome than symptomatology, explaining 20-60% of 
variance of it (30,32,33). More recently, social cognition, referred 
to as an array of abilities that involve cognitive capability applied 
to social situations (34), has attracted attention as a predictor of 
functional outcome (35). However, some previous studies have 
demonstrated that symptomatology is more influential in func-
tional outcome than cognitive function (20,36-38). The incon-
sistency among the previous findings can be explained mainly 
by difference of study design, sample population, sample size, 
cognitive tests and functional outcome scales. Especially, as for 
assessing cognitive function and functional outcome, research-
ers have used different neuropsychological tests and functional 
outcome scales. Therefore, comparisons across studies seem to 
be difficult.
In this situation, the National institute of Mental Health 
Measurement and Treatment Research to Improve Cognition 
in Schizophrenia (NIMH-MATRICS) Initiative developed a 
consensus cognitive battery for schizophrenia research that is 
the MATRICS Consensus Cognitive Battery (MCCB) (39). The 
MCCB is a comprehensive cognitive battery that contains not 
only neurocognitive domain but also social cognitive domain. On 
the other hand, as for functional outcome, there are no standard-
ized scales at present. However, the six scales selected by the 
Validation of Everyday Real-word Outcomes (VALERO) study 
are often used (40). The six scales are as follows : the Quality of 
Life Scale (QLS), the Specific Level of Functioning, the Social 
Behavior Schedule, the Social Functioning Scale, the Indepen-
dent Living Skills Schedule and the Life Skills Profile (LSP).
Regarding the direction of research in this area, it seems that 
interest has shifted from whether cognitive function is connected 
to functional outcome to how cognitive function is related to it. 
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Not all types of cognitive function are equally important when it 
comes to navigating the real world (22), and as far as we know, 
it seems unclear which cognitive domain is related to which 
aspect of functional outcome. Our research group has reported 
that particularly Symbol Coding test to evaluate speed of pro-
cessing was correlated with the QLS scores (18,20). Besides our 
study, since the MCCB was developed, several studies have also 
reported the relationship between cognitive function measured 
by it and functional outcome (41-51). However, to our knowledge, 
among those studies, few studies evaluated functional outcome 
using the LSP (48).
Although one of the ultimate treatment goals of schizophrenia 
is thought to be an improvement in functional outcome such 
as employment and social activities, many of schizophrenia 
patients have not accomplished it. For example, the employment 
rate is as low as about 10-20% (52-54). Therefore, becoming able 
to live well in a community is a crucial first step to lead to good 
functional outcome. To assess the ability to complete the first 
step, the LSP is considered suitable because it was selected as 
one of the everyday living skills scales in the VALERO study 
(40).
The purpose of the present study was to clarify the relation-
ship between life skills measured by the LSP and other clinical 
factors including cognitive function measured by the MCCB in 
people with schizophrenia. 
METHODS
Participants
Fifty-one stabilized outpatients with a DSM-IV (55) diagnosis 
of schizophrenia were recruited from the Department of Psychi-
atry, Tokushima University Hospital. Patients with any organic 
central nervous system disorders, substance-related disorders, 
mental retardation or severe somatic disorders were excluded. 
After receiving explanations on the content and possible dis-
advantages of the study as well as confidentiality protection, 
participants gave written informed consent to participate in the 
current study. They had been receiving regular outpatient treat-
ment and had not been hospitalized in the previous 6 months due 
to exacerbation of psychiatric symptoms.
This study was approved by the Ethics Committee of Tokushi-
ma University.
Instruments
To assess life skills, we used the LSP that was developed by 
Rosen et al. (56) as a measure of functioning in chronic men-
tal patients. The reliability and validity of the scale have been 
already confirmed (56,57). Family members, psychiatric pro-
fessionals, or case workers can be used as the informant in the 
interview (40). This instrument consists of five subscales mea-
sured by a total 39 items. Each item is rated from 1 to 4. The five 
subscales are self-care, non-turbulence, socialization, communi-
cation, responsibility. Higher scores indicate a better functional 
outcome. In the present study, 50 of 51 cases were evaluated by 
family members living together, and one case by a home helper.
Regarding evaluation of cognitive function, we used the 
MCCB which has been developed as a comprehensive measure 
of cognitive domains significantly impaired in schizophrenia 
patients. The MCCB consists of ten tests that measure seven 
cognitive domains. They are as follows : speed of processing 
(Brief Assessment of Cognition in Schizophrenia-Symbol Coding 
[BACS-SC], Category Fluency Animal Naming [Fluency] and 
Trail Making Test Part A [TMT-A]), attention/vigilance (Con-
tinuous Performance Test-Identical Pairs [CPT-IP]), working 
memory (Wechsler Memory Scale III Spatial Span [WMS-III 
SS] and Letter Number Span [LNS]), verbal learning (Hopkins 
Verbal Learning Test-Revised [HVLT-R]), visual learning (Brief 
Visuospatial Memory Test-Revised [BVMT-R]), reasoning and 
problem solving (Neuropsychological Assessment Battery [NAB] 
Maze), and social cognition (Mayer-Salovey-Caruso-Emotional 
Intelligence Test [MSCEIT] Managing Emotions [ME]) (39). 
Each raw score for the ten subtests was standardized to the 
T-score (mean = 50, SD = 10). For the cognitive domain consist-
ing of more than one test (speed of processing and working mem-
ory), the domain T-score was derived from a composite of the test 
scores within each domain, and for the other cognitive domains, 
T-score represents the domain score. The MCCB composite score 
gives equal weighting to each of the seven cognitive domains. 
The MCCB has good test-retest reliability, practicability and 
tolerability (39), and it is reported that the Japanese version 
of the MCCB (MCCB-J) has good psychometric properties and 
validity (58). In the present study, data were collected using the 
Japanese version by clinical psychologists who were well trained 
for the use of it.
Clinical symptoms were evaluated with the Positive and Nega-
tive Syndrome Scale (PANSS) and the Calgary Depression Scale 
for Schizophrenia (CDSS). The PANSS is composed of 30 items 
and higher scores represent a greater level of symptom severity 
(59). Experienced psychiatrists conducted the interviews accord-
ing to the Evaluation Manual for the PANSS (60). Particularly, 
depressive symptom was strictly evaluated with the CDSS that 
was specifically developed to distinguish depressive symptom 
from positive and negative symptom or antipsychotic-induced 
adverse effects. The scale is a 9-item questionnaire (depression, 
hopelessness, self-depreciation, guilty ideas of reference, patho-
logical guilt, morning depression, early wakening, suicide and 
observed depression) and higher scores represent a greater level 
of depression. The reliability and validity of the scale have been 
already confirmed (61,62).
Drug-induced extrapyramidal adverse effects were evaluat-
ed using the Drug-Induced Extrapyramidal Symptoms Scale 
(DIEPSS). The scale consists of eight individual parameters 
(gait, bradykinesia, sialorrhea, muscle rigidity, tremor, akathi-
sia, dystonia, and dyskinesia) and one global assessment. Higher 
scores represent a greater level of extrapyramidal adverse ef-
fects. In this study, we evaluated the extrapyramidal symptom 
score by summing eight individual parameters. Experienced 
psychiatrists conducted the interviews according to the Rater’s 
Manual for the DIEPSS (63).
Statistical analysis 
First, to clarify significant associations between the LSP 
scores and other clinical variables, Spearman’s rank correlation 
coefficients were calculated. We used the false discovery rate 
correction to adjust for multiple testing. Then the LSP total score 
and the subscale scores were chosen as dependent variables. 
Using the clinical variables that showed significant correlations 
with each dependent variable, stepwise regression analyses were 
performed to specify which clinical variables would be the best 
predictors of each dependent variable. Statistical analyses were 
carried out with IBM SPSS Statistics Version 22 for Windows 
(Japan IBM, Tokyo, Japan) and RStudio (RStudio Team. 2015. 
RStudio : Integrated Development for R. RStudio, Inc., Boston, 
MA. URL http://www.rstudio.com/.).
RESULTS
roughoTable 1 presents the demographic characteristics and 
clinical variables of the participants. All participants were Jap-
anese, and 26 were men and 25 women. Their mean age was 
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38.91 years (SD = 10.73). Doses of antipsychotics were converted 
to chlorpromazine equivalents according to the conversion chart 
(64).
Spearman rank correlation coefficients were calculated to 
study the relationship between the LSP and clinical variables 
because most of the data were non-normal distribution. Table 2 
shows the results of the correlation analyses between the LSP 
scores and the MCCB cognitive domain scores. Neither the 
MCCB cognitive domain score nor composite score was signifi-
cantly correlated with the LSP scores. In addition to that, each 
subtest score of the MCCB also have no significant correlation 
with the LSP scores.
The results of the correlation analyses between the LSP scores 
and other clinical variables are shown in Table 3. The PANSS 
positive syndrome scale score was significantly correlated with 
the LSP total score ( r = -0.38, p < 0.05) and communication sub-
scale score ( r = -0.47, p < 0.01). The PANSS negative syndrome 
scale score had significant correlations with the LSP total score 
Table 1.　Demographic characteristics of participants 
n (men/women) 51 (26/25)
Age (years) 38.91 ± 10.73
Duration of illness (years) 15.05 ± 9.10
Number of hospitalization 1.55 ± 1.49
Dose of antipsychotics (mg/day)* 545.14 ± 399.03
























PANSS Total 75.39 ± 14.64
Positive syndrome 16.82 ± 4.53
Negative syndrome 20.39 ± 5.50
CDSS (Total) 3.51 ± 2.96
DIEPSS (Total) 1.12 ± 1.07

















Verbal learning (HVLT-R) 39.75 ± 13.25
Visual learning (BVMT-R) 42.92 ± 10.44
Reasoning and problem solving
 (NAB Maze)
38.25 ± 9.82
Social cognition (MSCEIT ME) 26.61 ± 7.78
Composite score 19.10 ± 18.68
LSP Total 135.27 ± 11.97
Self-care 33.61 ± 4.18
Non-turbulence 44.90 ± 3.86
Socialization 16.49 ± 3.67
Communication 21.59 ± 2.44
Responsibility 18.69 ± 1.67
Note : Data are expressed as mean ± SD unless otherwise specified. *Chlorpromazine equivalent.
PANSS ; Positive and Negative Syndrome Scale ; CDSS : Calgary Depression Scale for Schizophrenia, DIEPSS ; Drug-
Induced Extrapyramidal Symptoms Scale, MCCB  Measurement and Treatment Research to Improve Cognition in 
Schizophrenia Consensus Cognitive Battery, BACS-SC ; Brief Assessment of Cognition in Schizophrenia-Symbol Coding, 
Fluency ; Category Fluency Animal Naming, TMT-A ; Trail Making Test Part A, CPT-IP ; Continuous Performance Test-
Identical Pairs, WMS-III SS ; Wechsler Memory Scale III Spatial Span, LNS ; Letter Number Span, HVLT-R ; Hopkins 
Verbal Learning Test-Revised, BVMT-R ; Brief Visuospatial Memory Test-Revised, NAB ; Neuropsychological Assessment 
Battery, MSCEIT ME ; Mayer-Salovey-Caruso-Emotional Intelligence Test Managing Emotions, LSP ; Life Skills Profile
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Note : Spearman rank correlations (false discovery rate correction). *p < 0.05; **p < 0.01. Figures in the parentheses 
show p values. 
MCCB ; Measurement and Treatment Research to Improve Cognition in Schizophrenia, LSP ; Life Skills Profile





































































































Notes : Spearman rank correlations (false discovery rate correction). *p < 0.05; **p < 0.01. Figures in the parentheses 
show p values.
MCCB ; Measurement and Treatment Research to Improve Cognition in Schizophrenia, LSP ; Life Skills Profile, 
PANSS ; Positive and Negative Syndrome Scale, CDSS ; Calgary Depression Scale for Schizophrenia, DIEPSS ; Drug 
Induced Extrapyramidal Symptoms Scale
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( r = -0.45, p < 0.01), self-care subscale score ( r = -0.48, p < 0.01), 
socialization subscale score ( r = -0.45, p < 0.01), and commu-
nication subscale score ( r = -0.39, p < 0.05). The CDSS total 
score was significantly correlated with the LSP total score ( r = 
-0.44, p < 0.01), self-care subscale score ( r = -0.48, p < 0.01), and 
socialization subscale score ( r = -0.41, p < 0.05). The DIEPSS 
score showed significant correlations with the LSP total score 
( r = -0.47, p < 0.01), self-care subscale score ( r = -0.43, p < 0.01), 
socialization subscale score ( r = -0.44, p < 0.01), and communica-
tion subscale score ( r = -0.38, p < 0.05). However, no significant 
correlation was found between the LSP scores and duration of 
illness, number of hospitalization, and dose of antipsychotics.
Table 4 shows the results of stepwise regression analyses on 
the LSP scores. The PANSS negative syndrome scale score sig-
nificantly predicted the LSP total score, self-care subscale score, 
and socialization subscale score. The CDSS score significantly 
predicted the LSP total score, self-care subscale score, and so-
cialization subscale score. The PANSS positive syndrome scale 
score significantly predicted the LSP communication subscale 
score. The CDSS score was stronger predictor of the LSP total 
score (β = -0.44, p = 0.0004) than the PANSS negative syndrome 
scale score (β = -0.37, p = 0.0020).
 
DISCUSSION
As for the relationship between cognitive function and func-
tional outcome, it is reported that verbal memory, working 
memory, executive function and vigilance were significantly 
associated with functional outcome (29-31). Moreover, in a recent 
meta-analysis study, Fett et al. (35) revealed that a variety of 
neurocognitive domains such as reasoning and problem solving, 
processing speed, attention and vigilance, working memory, ver-
bal learning and memory, visual learning and memory, verbal 
fluency, and overall neurocognition are significantly associated 
with functional outcome. Concerning social cognition, their me-
ta-analysis study also showed that social cognition, particularly 
theory of mind was more strongly associated with functional 
outcome than neurocognition (35).
There are some existing literatures investigating the relation 
between cognitive function and life skills assessed with the LSP. 
Norman et al. (38) reported that neurocognitive functions evalu-
ated by several cognitive measures were not correlated with the 
LSP scores at all. Using the database of VALERO study Phase 
I, Sabbag et al. (48) showed that the LSP summary scores were 
not related to neurocognition evaluated by the modified MCCB 
which did not include the MSCEIT. Farreny et al. (65) reported 
that executive function evaluated by the Behavioral Assessment 
of the Dysexecutive Syndrome was not correlated with the LSP 
scores at baseline in the cognitive remediation study. On the 
other hand, Stratta et al. (66) showed that executive function 
evaluated by Wisconsin Card Sorting Test was related to the 
LSP scores. Considering those previous findings, the relation 
between cognitive function and life skills assessed with the LSP 
still seems unclear.
As for the studies using the QLS as a measure of functional 
outcome, our research group has reported that Symbol Coding 
subtest of the Brief Assessment of Cognition in Schizophrenia 
(BACS) and the MCCB to evaluate speed of processing was 
correlated with the QLS scores and this subtest was an inde-
pendent predictor of the QLS scores (18,20). Other studies also 
suggest that speed of processing is closely related to QLS scores 
(45,67). Moreover, several previous studies showed that other 
cognitive domains such as executive function, verbal memory, 
working memory and social cognition were associated with the 
QLS (16,68-76). From these findings, it seems certain that the 
QLS is related to cognitive function to some extent. The QLS is 
composed of many items to evaluate high social functions such 
as work and social activities (77). On the other hand, the LSP 
evaluates life skills, especially rather basic ones that people need 
to have in daily life. Therefore, although cognitive function is re-
lated to functional outcome (29-31,35), the results of the present 
study indicate that cognitive function may not play a function in 
basic life skills in people with schizophrenia.
Table 4.　Results of stepwise regression analyses on LSP











































Note : *p < 0.05; **p < 0.01, ***p < 0.001. Figures in the parentheses show p values.
LSP ; Life Skills Profile, CDSS ; Calgary Depression Scale for Schizophrenia, PANSS ; Positive and Negative Syndrome 
Scale
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Next, in regard to the clinical variables other than cognitive 
function, the results of the present study indicate that positive 
and negative symptoms, extrapyramidal symptom and depres-
sive symptom are significantly related to low life skills. Partic-
ularly, negative and depressive symptoms are considered key 
factors influencing wide range of life skills. These results are 
largely consistent with our research group’ previous study (8). 
Recently, Puig et al. (78) also reported that negative symptom 
is related to the LSP communication-social contact subscale 
score. Matsuda et al. (79) found that improvement on negative 
symptom was significantly related to improvement on the LSP 
socialization score in the follow-up study of first-episode schizo-
phrenia patients. On the other hand, Norman et al. (38) showed 
that positive symptom is more tied to the LSP scores than neg-
ative symptom.
The results of the present study clearly showed that cognitive 
function does not influence life skills and depressive symptom 
is a stronger predictor of low life skills than negative symp-
tom. This is a novel finding in the present study. Considering 
these results, interventions to treat depressive symptom may 
be particularly important to improve life skills in people with 
schizophrenia.
The present study has some limitations. First, since it was a 
cross-sectional study, the causal relationship between clinical 
variables and life skills could not be identified. Second, the 
sample size is small. So, further research with larger sample 
size may be needed to confirm the results. Third, as the sample 
consisted entirely of stabilized outpatients, the results may not 
be able to apply to the whole schizophrenia patients.
In conclusion, the results of the present study indicate that 
cognitive function is not associate with life skills evaluated by 
the LSP, but clinical symptoms such as negative and depressive 
symptoms have significant impacts on the skills in people with 
schizophrenia.
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